AllianzIM U.S. Equity Buffer15 Uncapped Mar ETF (MARU) seeks to provide exposure to U.S. equity market returns with built-in downside protection over a specific outcome period ending in March. This defined outcome ETF uses options strategies to buffer against the first 15% of losses while maintaining unlimited upside participation in market gains.
How It Works
MARU employs a sophisticated options overlay strategy that combines long positions in U.S. equity exposure with protective put options and sold call spreads. The fund resets annually in March, establishing new buffer and participation levels based on prevailing options prices. This actively managed approach requires continuous monitoring and adjustment of the options portfolio to maintain the targeted 15% downside buffer while preserving uncapped upside potential throughout the outcome period.
Key Features
- Provides 15% downside buffer protection, absorbing first 15% of U.S. equity market losses during the outcome period
- Maintains unlimited upside participation unlike capped buffer ETFs, allowing full benefit from strong market performance
- Annual March reset allows investors to lock in new protection levels and restart the outcome period
Risks
- This ETF can lose value beyond the 15% buffer if U.S. equity markets decline more than 15% during the outcome period, with losses accelerating dollar-for-dollar thereafter
- Options strategies may underperform during volatile markets due to timing mismatches, bid-ask spreads, and the complexity of maintaining precise hedge ratios
- Early exit before the March outcome period ends may result in losses even if underlying markets are positive due to options time decay
Who Should Own This
Best suited for conservative to moderate investors with 1-year investment horizons seeking equity exposure with downside protection. Requires medium risk tolerance and understanding of options mechanics. Works as a satellite holding (10-20% allocation) for investors wanting market participation with built-in loss mitigation during the specific March-to-March outcome period.